## **SHORT COMMUNICATION**

## α. -Microglobulin (HC protein) in human hepatocellular carcinoma

C. Vincent<sup>1</sup>, M.C. Kew<sup>2</sup>, P. Bouic<sup>1</sup>, M. Flacher<sup>1</sup> & J.P. Revillard<sup>1</sup>

<sup>1</sup>Laboratory of Immunology, INSERM U80 CNRS UA 1177 UCBL, Hôpital E. Herriot, Pav. P, 69437 Lyon Cedex 3, France; and <sup>2</sup>Department of Medicine, University of Witwatersrand, Johannesburg, South Africa.

 $\alpha_1$ -Microglobulin ( $\alpha_1$ -m) is a highly glycosylated polypeptide of 182 amino acids associated with a brown chromophore (Ekström et al., 1975; Lopez Otin et al., 1984). The molecule is heterogeneous in charge and was described as HC protein (Tejler & Grubb, 1976) or  $\alpha_1$ -microglycoprotein (Seon & Pressmann, 1978). It occurs in biological fluids as a 31 kDa monomer and as a 90 kDa component covalently associated to one a chain of monomeric immunoglobulin A (IgA) (Grubb et al., 1983; Vincent et al., 1985). The  $\alpha_1$ -m gene is associated with a gene coding for the HI-30 domain of interα-trypsin inhibitor, one of the acute phase proteins (Kaumeyer et al., 1986). The human 31 kDa  $\alpha_1$ -m was shown to be synthesised by fetal liver explants (Tejler et al., 1978) and we recently reported that the molecule was produced in vitro by several human hepatoma cell lines but not by lymphoma or plasmocytoma cell lines (Vincent et al., 1987). For these reasons we have determined serum levels of  $\alpha_1$ -m in a large series of patients suffering from primary hepatocellular carcinoma in order to evaluate the possible use of this molecule as an additional tumour marker. The data show that 31 kDa  $\alpha_1$ -m levels are usually not increased in this disease, whereas the 90 kDa component levels are elevated in some cases.

Our study involved a hundred South African Blacks with histologically proven hepatocellular carcinoma. They included 11 women and 89 men whose ages ranged from 20 to 73 years (median 39). Seventy-seven healthy South African Black subjects served as controls. All serum samples were sent frozen in dry ice from South Africa and were stored at  $-40^{\circ}$ C until use.

The differential quantitation of 31 kDa and IgA-associated 90 kDa  $\alpha_1$ -m in unfractionated sera was performed by

enzyme linked immunosorbent assay (ELISA) as previously described (Vincent & Revillard, 1985). Briefly, the monoclonal antibody 832 ALB which binds both forms of  $\alpha_1$ -m with high affinity  $(1.4\times10^{10}\,\text{L/M})$  was used as solid phase. The binding of serum  $\alpha_1$ -m was assessed by addition of polyconal immunopurified biotinylated antibodies specific for  $\alpha_1$ -m or for the heavy chain of IgA, then by incubation with peroxidase-streptavidin, addition of the substrate and recording of the absorbance at 280 nm. Interassay coefficients of variation did not exceed 16%. Normal levels of 31 kDa in 25 French adults were  $9.54\pm2.73\,\text{mg}\,\text{l}^{-1}$  (mean  $\pm$  s.d.). As regards  $90\,\text{kDa}$   $\alpha_1$ -m, normal levels in the same control group were  $101.9\pm36.6\,\text{kU}\,\text{l}^{-1}$  (Vincent & Revillard, 1987).

Albumin concentrations were measured by radial immuno-diffusion,  $\beta_2$ -microglobulin and IgA by competitive ELISA (Vincent & Revillard, 1986; Vincent et al., 1985).  $\alpha$ -Fetoprotein and HBs antigen were determined by solid phase radio-immunoassay,  $\gamma$ -glutamyl transpeptidase and alkaline phosphatase activities by routine biochemical methods. The upper limit values for serum 31 kDa and 90 kDa  $\alpha_1$ -m were defined by the 90th percentile of the control group (Soleberg, 1985). Comparisons between groups were based on the Mann-Whitney U test.

Individual serum levels of 31 kDa and 90 kDa  $\alpha_1$ -m are presented in Figure 1. In healthy subjects from South Africa serum levels of 31 kDa  $\alpha_1$ -m were similar to that of European controls whereas those of the 90 kDa form appeared to be slightly lower. Twenty-two patients had 31 kDa  $\alpha_1$ -m levels above the upper limit of control values but the distribution in patients did not differ from that of controls. As regards 90 kDa  $\alpha_1$ -m levels, 35 patients had elevated




Figure 1 Serum levels of 31 kDa  $\alpha_1$ -m (a) and IgA-associated 90 kDa  $\mu_1$ -m (b) in 100 patients with hepatocellular carcinoma (H) and 77 controls (C). The dashed lines indicate the median of the distribution in each group.

Correspondence: J.P. Revillard.

values and the overall distribution differed from that of healthy controls (P < 0.002, Mann-Whitney U test). Serum IgA concentrations were elevated in four of the patients and were not correlated with  $90\,\mathrm{kDa}$   $\alpha_1$ -m levels. No difference in  $\alpha_1$ -m levels was found between the 54 HBs antigen-positive and HBs antigen-negative patients. The concentrations of serum albumin were not correlated with those of  $\alpha_1$ -m. Finally,  $\alpha$ -fetoprotein was increased in 91% of patients' sera,  $\beta_2$ -microglobulin in 59%, alkaline phosphatase activity in 78% and  $\gamma$ -glutamyltranspeptidase in 94% but none of these biological parameters was correlated with  $\alpha_1$ -m levels.

Serum levels of 31 kDa  $\alpha_1$ -m were reported to rise in renal insufficiency (Itoh *et al.*, 1983; Yu *et al.*, 1983) and in a few patients with malignant tumours, including the only two cases of hepatoma that were investigated (Tagaki *et al.*,

1980). Immunohistochemical studies of normal human tissues showed that hepatocytes were intensely stained by anti- $\alpha_1$ -m antibodies along with macrophages and some lymphocytes (Bouic et al., 1984). Studies of human fetal livers revealed that fetal hepatocytes but not haematopoietic stem cells were strongly labelled by anti- $\alpha_1$ -m antibodies (Bouic et al., unpublished data). Furthermore, the protein was shown to be synthesised by human fetal liver explants (Tejler et al., 1978) and produced in high amounts by some human hepatocarcinoma cell lines (Vincent et al., 1987). Therefore  $\alpha_1$ -m was considered as a potential biologic marker of hepatocellular carcinoma. However, the present study demonstrates that this prediction was not confirmed, despite the significant elevation of  $90 \,\mathrm{kDa} \, \alpha_1$ -m in the patients group as compared with controls.

## References

- BOUIC, P., VINCENT, C. & REVILLARD, J.P. (1984). Localization of  $\alpha_1$ -microglobulin (HC protein) in normal human tissues: an immunohistochemical study using monoclonal antibodies. *Histochem. J.*, **16**, 1311.
- EKSTRÖM, B., PETERSON, P.A. & BERGGARD, I. (1975). A urinary and plasma  $\alpha_1$ -glycoprotein of low molecular weight: isolation and some properties. *Biochem. Biophys. Res. Comm.*, **65**, 1427.
- GRUBB, A.O., LOPEZ, C., TEJLER, L. & MENDEZ, E. (1983). Isolation of human complex-forming glycoprotein, heterogeneous in charge (protein HC), and its IgA complex from plasma. *J. Biol. Chem.*, **258**, 14698.
- KAUMEYER, J.F., POLAZZI, J.O. & KOTICK, M.P. (1986). The mRNA for a proteinase inhibitor related to the HI-30 domain of inter-α-trypsin inhibitor also encodes α<sub>1</sub>-microglobulin (protein HC). Nucl. Acids Res., 14, 7839.
  ITOH, Y., ENOMOTO, H., TAGAKI, K. & KAWAI, T. (1983). Clinical
- ITOH, Y., ENOMOTO, H., TAGAKI, K. & KAWAI, T. (1983). Clinical usefulness of serum  $\alpha_1$ -microglobulin as a sensitive indicator for renal insufficiency. *Nephron*, **33**, 69.
- LOPEZ OTIN, C., GRUBB, A.O. & MENDEZ, E. (1984). The complete amino-acid sequence of human complex-forming glycoprotein heterogeneous in charge (protein HC) from one individual. *Arch. Biochem. Biophys.*, 228, 544.
- SEON, K. & PRESSMAN, D. (1978). Unique human glycoprotein,  $\alpha_1$ -microglycoprotein: isolation from the urine of a cancer patient and its characterization. *Biochemistry*, 17, 2815.
- SOLEBERG, H.E. (1983). The theory of reference values (part 5). J. Clin. Chem. Biochem., 21, 749.
- TAGAKI, K., ITOH, Y., EMONOTO, H., KOYOMAISHI, Y., MAEDA, K. & KAWAI, T. (1980). A comparative study of serum  $\alpha_1$ -microglobulin and  $\beta_2$ -microglobulin levels in cancerous and other diseases. *Clin. Chim. Acta*, **108**, 277.

- TEJLER, L., ERIKSSON, S., GRUBB, A.O. & ASTEDT, B. (1978). Production of protein HC by human fetal liver explants. *Biochem. Biophys. Acta*, **542**, 506.
- TEJLER, L. & GRUBB, A.O. (1976). A complex-forming glycoprotein heterogeneous in charge and present in human plasma, urine and cerebrospinal fluid. *Biochem. Biophys. Acta*, **439**, 82.
- VINCENT, C., BOUIC, P., BATAILLE, R. & REVILLARD, J.P. (1985). Complexes of α<sub>1</sub>-microglobulin and monomeric IgA in multiple myeloma and normal human sera. *Mol. Immunol.*, **22**, 663.
- VINCENT, C., MARCEAU, M., BLANGARIN, P., BOUIC, P., MADJAR, J.J. & REVILLARD, J.P. (1987). Purification of  $\alpha_1$ -microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with  $\alpha_1$ -microglobulin synthesized by human hepatocytes. *Eur. J. Biochem.*, **165**, 699.
- VINCENT, C. & REVILLARD, J.P. (1985). Differential measurement by ELISA of free and IgA bound  $\alpha_1$ -microglobulin in human serum without prior fractionation. J. Immunol. Methods, 82, 111.
- VINCENT, C. & REVILLARD, J.P. (1986). β<sub>2</sub>-microglobulin. In Methods of Enzymatic Analysis, Proteins and Peptides, Bergmeyer, H.U. (ed) Vol. 9, p. 248. VCH: Weinheim, FRG.
  VINCENT, C. & REVILLARD, J.P. (1987). α<sub>1</sub>-microglobulin (HC
- VINCENT, C. & REVILLARD, J.P. (1987). α<sub>1</sub>-microglobulin (HC protein) and its IgA complex in human secretory fluids. In Recent Advances in Mucosal Immunology (part B), Mestecky, J., McGhee, J.R., Bienenstock, J. & Orga, P.L. (eds) p. 1231. Plenum: New York.
- YU, H., YANAGISAWA, Y., FORBES, M.A., COOPER, E.H. & CROCKSON, R.A. (1983). α<sub>1</sub>-microglobulin: an indicator protein for renal tubular function. J. Clin. Pathol., 36, 253.